title: Antiangiogenic systemic gene therapy combined with doxorubicin administration induced caspase 8 and 9-mediated apoptosis in endothelial cells and an anti-metastasis effect.
abstract: Ad-PPE-Fas-c is an adenovector that expresses Fas-c under the control of the modified pre-proendothelin-1 (PPE-1) promoter. Fas-c is a chimeric death receptor containing the extracellular portion of tumour necrosis factor 1 receptor (TNFR1) and the transmembrane and intracellular portion of Fas. We recently demonstrated that Ad-PPE-Fas-c induced Fas-receptor-mediated endothelial cell apoptosis. Previously, doxorubicin was shown to enhance Fas-receptor clustering and the induction of its cascade. Therefore, the goal of this work was to test whether doxorubicin augments the capacity of Ad-PPE-Fas-c to induce endothelial cell apoptosis and to elucidate whether either the death-receptor-mediated apoptotic cascade or the mitochondria-associated apoptotic cascade is involved in the combined treatment effect. We found that a combined treatment of Ad-PPE-Fas-c and doxorubicin synergistically induced a reduction in endothelial cell viability and apoptosis. z-IETD-FMK, a caspase-8 inhibitor, and z-LEHD-FMK, a caspase-9 inhibitor, significantly decreased apoptosis induced by the combined treatment. Systemically administered combined therapy significantly reduced the lung metastases burden (70%) in mice as compared to each treatment alone. Thus, a combined treatment of Ad-PPE-Fas-c gene therapy and chemotherapy may be effective in the treatment of metastatic diseases and both the Fas cascade and the mitochondria-associated cascade are essential for this effect.
authors.affiliation: Vascular Biogenics Ltd., Or Yehuda, Israel.
authors.forename: M
authors.initials: M
authors.lastname: Peled
authors.forename: A
authors.initials: A
authors.lastname: Shaish
authors.forename: S
authors.initials: S
authors.lastname: Greenberger
authors.forename: A
authors.initials: A
authors.lastname: Katav
authors.forename: I
authors.initials: I
authors.lastname: Hodish
authors.forename: D
authors.initials: D
authors.lastname: Ben-Shushan
authors.forename: I
authors.initials: I
authors.lastname: Barshack
authors.forename: I
authors.initials: I
authors.lastname: Mendel
authors.forename: L
authors.initials: L
authors.lastname: Frishman
authors.forename: R
authors.initials: R
authors.lastname: Tal
authors.forename: L
authors.initials: L
authors.lastname: Bangio
authors.forename: E
authors.initials: E
authors.lastname: Breitbart
authors.forename: D
authors.initials: D
authors.lastname: Harats
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D053181:Caspase 8 / Q000378:metabolism*; D053453:Caspase 9 / Q000378:metabolism*; D002417:Cattle; D002478:Cells, Cultured; D004317:Doxorubicin / Q000008:administration & dosage*; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects*; D015316:Genetic Therapy; D005822:Genetic Vectors; D051379:Mice; D008810:Mice, Inbred C57BL; D009362:Neoplasm Metastasis / Q000517:prevention & control*; D009389:Neovascularization, Pathologic / Q000517:prevention & control*
chemical_list: D004317:Doxorubicin; D053181:Caspase 8; D053453:Caspase 9